CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR).
CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM.
性状
Solid
体外研究(In Vitro)
CH-223191 (0.1-10 μM; pre-treated 1 hour) inhibits TCDD-caused cytochrome P450 1A1 mRNA expression in a in dose-dependent manner.
CH-223191 (0.1-10 μM; pre-treated 1 hour) causes a concentration-dependent inhibition of TCDD-induced cytochrome P450 enzyme activity.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
RT-PCR
Cell Line:
HepG2 cells
Concentration:
0.1-10 μM
Incubation Time:
1 hour
Result:
Caused inhibition of TCDD-induced cytochrome P450 mRNA expression.
Western Blot Analysis
Cell Line:
HepG2 cells
Concentration:
0.1-10 μM
Incubation Time:
1 hour
Result:
Decreased TCDD-caused cytochrome P450 1A1 protein Treatment.
体内研究(In Vivo)
CH-223191 (10 mg/kg; once a day; 25 days) suppresses cytochrome P450 1A1 expression and the intrahepatocyte fat content in liver, reduces activity of AST and ALT in TCDD-treated mice.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male ICR mice (6 weeks old)
Dosage:
10 mg/kg
Administration:
10 mg/kg; once a day; 25 days
Result:
Prevented TCDD-elicited cytochrome P450 induction, liver toxicity, and wasting syndrome in mice.